Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03351803 · ClinicalTrials.gov registry record
BRCA Founder OutReach (BFOR) Study
A clinical trial of BRCA1 Mutation and BRCA2 Mutation, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 5,412
- Enrollment target
- 5
- Study locations
NCT03351803: Active study of BRCA1 Mutation and BRCA2 Mutation, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03351803 is a study of BRCA1 Mutation and BRCA2 Mutation that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 5,412 participants, above the 216-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (2406% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03351803, a study of BRCA1 Mutation and BRCA2 Mutation, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 5,412 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to learn how to provide BRCA gene testing to a larger number of people as well as to make testing part of a person's regular medical care.
Conditions Studied
Interventions
- OTHER BFOR Digital Health solution/Web Portal
Study Locations (5)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
California
- University of California, Los Angeles - Los Angeles
New York
- Memorial Sloan - Kettering Cancer Center - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,412 participants |
| Start Date | 2017-11-10 |
| Est. Completion | 2026-05-10 |
What the registry record for NCT03351803 still lists
NCT03351803 is an observational study that tracks outcomes without assigning an intervention. Its 5,412 participants enrollment target places it among the larger protocols in the corpus, above the 216-participant average among 15 other BRCA1 Mutation trials with a reported enrollment target (2406% higher).
The record links to 2 conditions, with BRCA1 Mutation appearing as the primary indexed condition, and to 1 intervention - of which BFOR Digital Health solution/Web Portal is the first listed.
NCT03351803 lists 5 locations in 4 states (Massachusetts, California, New York).
Frequently Asked Questions
What is clinical trial NCT03351803 about?
NCT03351803 is a clinical study titled "BRCA Founder OutReach (BFOR) Study". The purpose of this study is to learn how to provide BRCA gene testing to a larger number of people as well as to make testing part of a person's regular medical care.
What is the current status of trial NCT03351803?
This trial is currently active not recruiting. The enrollment target is 5,412 participants. The study started on 2017-11-10. Estimated completion is 2026-05-10.
What conditions does trial NCT03351803 study?
This clinical trial studies the following conditions: BRCA1 Mutation, BRCA2 Mutation.
What interventions are being tested in trial NCT03351803?
The interventions under investigation include: BFOR Digital Health solution/Web Portal (OTHER).
Who is sponsoring clinical trial NCT03351803?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03351803 being conducted?
This trial has 5 study locations across California, Massachusetts, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for BRCA1 Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03351803's enrollment target sits among peer trials
5,412 1st of 15 higher than 15 of 15 other BRCA1 Mutation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other BRCA1 Mutation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results
RECRUITING · NA
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Combination Therapy in Cancers With Mutations in DNA Repair Genes
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
RECRUITING · Phase 1
-
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI